新闻

• 2026年08月20日 Senju initiated Phase III Clinical Trials in Japan for "SJP-0049" for the treatment of Allergic Conjunctivitis（PDF）
• 2026年06月01日 Launch of Distribution of 3in1Smart and SPM-700（PDF）
• 2026年04月06日 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF）
• 2025年12月22日 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V member 1 Inhibition（PDF）